{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000762","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.742078+00:00","generated_at":"2026-06-07T02:32:12.876574+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Foghorn outlines 2024 pipeline milestones; AML combo data expected H2, six INDs over four years","bullets":["FHD-286 Phase 1 combination study in AML continues; first data expected H2 2024.","Preclinical combo data with TKIs in EGFR/KRAS resistance expected Q2 2024.","Selective EP300 and CBP degraders show efficacy without thrombocytopenia; CBP IND enabling studies targeted before end of 2024.","At least six new INDs planned over next four years across >20 tumor types.","Cash $259.9M as of Sep 30, 2023; runway into H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000762","json":"https://secwatch.observer/filing/0001628280-24-000762.json","markdown":"https://secwatch.observer/filing/0001628280-24-000762.md","text":"https://secwatch.observer/filing/0001628280-24-000762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/0001628280-24-000762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/fhtx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:32:12.876574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}